Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05375838 · ClinicalTrials.gov registry record · Phase 1
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old
A Phase 1 study, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 1
- Development phase
- 550
- Enrollment target
NCT05375838 is a Phase 1 study that has completed, run by ModernaTX. The registered enrollment target is 550 participants.
The verdict
NCT05375838, a Phase 1 study, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 550 participants
- Enrollment target
Study Summary
The primary goal of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1073 compared to co-administered mRNA-1010 and mRNA-1273 vaccines and to the individual vaccines alone in healthy participants.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL mRNA-1273
- BIOLOGICAL mRNA-1010
- BIOLOGICAL mRNA-1073
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 550 participants |
| Start Date | 2022-05-13 |
| Est. Completion | 2022-12-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05375838
The ClinicalTrials.gov registry entry for NCT05375838 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 550 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT05375838 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05375838 about?
NCT05375838 is a clinical study titled "A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old". The primary goal of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1073 compared to co-administered mRNA-1010 and mRNA-1273 vaccines and to the individual vaccines alone in healthy participants.
What is the current status of trial NCT05375838?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 550 participants. The study started on 2022-05-13. Estimated completion is 2022-12-29.
What interventions are being tested in trial NCT05375838?
The interventions under investigation include: Placebo (BIOLOGICAL), mRNA-1273 (BIOLOGICAL), mRNA-1010 (BIOLOGICAL), mRNA-1073 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05375838?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.